• Network-Based Analysis of Fatal Comorbidities of COVID-19 and Potential Therapeutics

    22 days ago - By IEEE/ACM

    COVID-19 is a highly contagious disease caused by the severe acute respiratory syndrome coronavirus 2. The case-fatality rate is significantly higher in older patients and those with diabetes, cancer or cardiovascular disorders. The human proteins, angiotensin-converting enzyme 2 , transmembrane protease serine 2 and basigin , are involved in high-confidence host-pathogen interactions with SARS-CoV-2 proteins. We considered these three proteins as seed nodes and applied the random walk with restart method on the human interactome to construct a protein-protein interaction sub-network...
    Read more ...

     

  • Eukaryotic initiation factor-2, gamma subunit, suppresses proliferation and regulates the cell cycle via the MAPK/ERK signaling pathway in acute myeloid leukemia

    22 days ago - By Springer

    Abstract
    Purpose
    The expression of eukaryotic translation initiation factor-2 subunit 3 in patients with non-small cell lung and colorectal cancer is lower than that in healthy individuals. However, the functions of EIF2S3 remain unclear, and its study in leukemia has not been reported. The article aims to explore the role of EIF2S3 in AML and its underlying mechanism.
    Methods
    Reverse transcription-quantitative PCR was performed to evaluate the expression levels of EIF2S3, and its association with patient prognosis was determined. Inducible HEL-EIF2S3 and HL-60-EIF2S3 cell lines were...
    Read more ...

     

  • T Cell Populations Linked to Persistent COVID-19 Respiratory Disease

    T Cell Populations Linked to Persistent COVID-19 Respiratory Disease

    22 days ago - By Discovery's Edge

    Mayo Clinic researchers and collaborators report that persistent lung changes after COVID-19 in patients over 60 may be linked to specific populations of T cells. The small study of recovered patients, reported in Science Immunology , gets researchers closer to the cause of chronic respiratory disease kicked off by SARS-CoV-2 infection and suggests new potential avenues for therapy.
    The team, led by longtime collaborators Jie Sun, Ph.D. , a Mayo Clinic immunologist, and Robert Vassallo, M.D. , a Mayo Clinic pulmonologist, recruited 10 participants two to three months after they had been...
    Read more ...